Figure 3.

Cumulative incidence of receiving systemic chemotherapy based on the percentage of CADM1⁺ (D + N) cells. The use of topical chemotherapy, such as skin‐directed therapy and regional irradiation, were not counted as progression. iATL‐PI was categorized into three risk groups for clinical progression as follows: low risk, sIL‐2R ≤ 1000 U/mL; intermediate risk, 1000 U/mL < sIL‐2R ≤ 6000 U/mL; and high risk, sIL‐2R > 6000 U/mL. Cumulative incidence of receiving systemic chemotherapy in each group (A), in indolent adult T‐cell leukemia/lymphoma (ATL) cases (B), or in indolent ATL cases stratified by iATL‐PI (C). AC, asymptomatic carrier; ATL, adult T‐cell leukemia/lymphoma; iATL‐PI, indolent ATL prognostic index